- Home
- GXAI vs TLPH Comparison
GXAI vs TLPH Comparison
Compare GXAI & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GXAI
- TLPH
- Stock Information
- Founded
- GXAI 2021
- TLPH 2005
- Country
- GXAI United States
- TLPH United States
- Employees
- GXAI N/A
- TLPH N/A
- Industry
- GXAI
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- GXAI
- TLPH Health Care
- Exchange
- GXAI Nasdaq
- TLPH Nasdaq
- Market Cap
- GXAI 9.7M
- TLPH 10.6M
- IPO Year
- GXAI 2023
- TLPH 2011
- Fundamental
- Price
- GXAI $1.25
- TLPH $0.52
- Analyst Decision
- GXAI
- TLPH Strong Buy
- Analyst Count
- GXAI 0
- TLPH 1
- Target Price
- GXAI N/A
- TLPH $6.00
- AVG Volume (30 Days)
- GXAI 159.4K
- TLPH 50.8K
- Earning Date
- GXAI 08-12-2025
- TLPH 08-13-2025
- Dividend Yield
- GXAI N/A
- TLPH N/A
- EPS Growth
- GXAI N/A
- TLPH N/A
- EPS
- GXAI N/A
- TLPH N/A
- Revenue
- GXAI $27,740.00
- TLPH $27,000.00
- Revenue This Year
- GXAI N/A
- TLPH N/A
- Revenue Next Year
- GXAI N/A
- TLPH $14,533.26
- P/E Ratio
- GXAI N/A
- TLPH N/A
- Revenue Growth
- GXAI 9987.27
- TLPH N/A
- 52 Week Low
- GXAI $1.00
- TLPH $0.43
- 52 Week High
- GXAI $7.50
- TLPH $1.19
- Technical
- Relative Strength Index (RSI)
- GXAI 41.89
- TLPH 61.24
- Support Level
- GXAI $1.30
- TLPH $0.44
- Resistance Level
- GXAI $1.65
- TLPH $0.52
- Average True Range (ATR)
- GXAI 0.10
- TLPH 0.03
- MACD
- GXAI -0.02
- TLPH 0.01
- Stochastic Oscillator
- GXAI 4.77
- TLPH 93.89
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.